BPOM Publishes EUA Primary IndoVac Vaccine For Adults

Illustration - The IndoVac vaccine produced by Bio Farma. (ANTARA/HO Bio Farma).

JAKARTA - The Indonesian Food and Drug Supervisory Agency (BPOM) has issued an Emergency Use Authorization (EUA) for a domestic vaccine produced by PT Bio Farma, IndoVac.

"IndoVac's domestic vaccine from Bio Farma and Baylor College of Medicine (BCM) has already received EUA for adult primary vaccines," said Head of BPOM Penny K Lukito while attending the House of Representatives Commission IX Hearing Meeting (RDP), as reported by ANTARA, Wednesday, 28 September.

Penny said IndoVac was the second domestically made COVID-19 vaccine to receive the EUA BPOM RI, in addition to the mRNA platform vaccine produced by PT Etana.

Meanwhile, the InaVac vaccine produced by PT Biotis Pharmaceutical Indonesia in collaboration with Universitas Airlangga researchers is still completing the final phase of clinical trials for primary and booster vaccines.

Penny said the IndoVac Vaccine EUA is a requirement that must be met by producers before being released to the public. In addition, the EUA is also a follow-up ticket for clinical trials of booster or booster doses.

According to Penny, the IndoVac Vaccine has also received halal certification from the competent authorities in Indonesia after going through a series of inspections of the production process.

"All domestic vaccines are halal vaccines. Including the mRNA Ethane is also halal," he said.

Previously, the President Director of PT Bio Farma (Persero) Pharmaceutical BUMN, Honesti Basyir, stated that his party was ready to produce 20 million doses of IndoVac vaccine, for the initial stage.

This number can be increased to 40 million doses per year by 2023 with the addition of production facilities.

Furthermore, the production capacity can be increased again to 100 million doses per year by 2024, depending on the needs and demands.